ArticleBritish journal of cancer2012
Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- Trial
- Alkalization of the intracellular pH reprograms TNF-α signaling from inflammatory NF-κB activation to tumoricidal RIP kinase-dependent necroptosis in cancer cells.Acta pharmacologica Sinica · 2026Article
- Targeting pH regulation in cancer: combined mild alkaline treatment and NHE1 inhibition as a potential therapy for clear cell renal cell carcinoma.Molecular and cellular biochemistry · 2026Article
- Bicarbonate-integrated transarterial chemoembolization (TACE) in real-world hepatocellular carcinoma.Signal transduction and targeted therapy · 2025Article
- Acid affairs in anti-tumour immunity.Cancer cell international · 2024Review
- Exploring the Potential Use of Natural Products Together with Alkalization in Cancer Therapy.Pharmaceutics · 2024Review
- Biochemical hallmarks-targeting antineoplastic nanotherapeutics.Bioactive materials · 2024Review
- Tumor Biochemical Heterogeneity and Cancer Radiochemotherapy: Network Breakdown Zone-Model.Entropy (Basel, Switzerland) · 2022Article
- Alkalization of cellular pH leads to cancer cell death by disrupting autophagy and mitochondrial function.Oncogene · 2022Article
- Tumor Hypoxia Heterogeneity Affects Radiotherapy: Inverse-Percolation Shell-Model Monte Carlo Simulations.Entropy (Basel, Switzerland) · 2022Article
- What do cellular responses to acidity tell us about cancer?Cancer metastasis reviews · 2021Review
- Calcium carbonate nanoparticles stimulate cancer cell reprogramming to suppress tumor growth and invasion in an organ-on-a-chip system.Scientific reports · 2021Article
- Noninvasive Detection of Extracellular pH in Human Benign and Malignant Liver Tumors Using CEST MRI.Frontiers in oncology · 2020Article
- Targeting tumor-associated acidity in cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2018Review
- Mathematical Modeling of the Function of Warburg Effect in Tumor Microenvironment.Scientific reports · 2018Article
- Quantification of lactate from various metabolic pathways and quantification issues of lactate isotopologues and isotopmers.Scientific reports · 2017Article
- Tris-base buffer: a promising new inhibitor for cancer progression and metastasis.Cancer medicine · 2017Article
- Monodispersed calcium carbonate nanoparticles modulate local pH and inhibit tumor growth in vivo.Nanoscale · 2016Article
- Heterogeneity and proliferation of invasive cancer subclones in game theory models of the Warburg effect.Cell proliferation · 2015Article
- Evaluations of extracellular pH within in vivo tumors using acidoCEST MRI.Magnetic resonance in medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundClinical positron emission tomography imaging has demonstrated the vast majority of human cancers exhibit significantly increased glucose metabolism when compared with adjacent normal tissue, resulting in an acidic tumour microenvironment. Recent studies demonstrated reducing this acidity through systemic buffers significantly inhibits development and growth of metastases in mouse xenografts.
methodsWe apply and extend a previously developed mathematical model of blood and tumour buffering to examine the impact of oral administration of bicarbonate buffer in mice, and the potential impact in humans. We recapitulate the experimentally observed tumour pHe effect of buffer therapy, testing a model prediction in vivo in mice. We parameterise the model to humans to determine the translational safety and efficacy, and predict patient subgroups who could have enhanced treatment response, and the most promising combination or alternative buffer therapies.
resultsThe model predicts a previously unseen potentially dangerous elevation in blood pHe resulting from bicarbonate therapy in mice, which is confirmed by our in vivo experiments. Simulations predict limited efficacy of bicarbonate, especially in humans with more aggressive cancers. We predict buffer therapy would be most effectual: in elderly patients or individuals with renal impairments; in combination with proton production inhibitors (such as dichloroacetate), renal glomular filtration rate inhibitors (such as non-steroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors), or with an alternative buffer reagent possessing an optimal pK of 7.1-7.2.
conclusionOur mathematical model confirms bicarbonate acts as an effective agent to raise tumour pHe, but potentially induces metabolic alkalosis at the high doses necessary for tumour pHe normalisation. We predict use in elderly patients or in combination with proton production inhibitors or buffers with a pK of 7.1-7.2 is most promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.